MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
28.69
+0.26
+0.91%
After Hours: 29.30 +0.61 +2.13% 19:07 06/26 EDT
OPEN
28.08
PREV CLOSE
28.43
HIGH
29.32
LOW
27.89
VOLUME
2.83M
TURNOVER
--
52 WEEK HIGH
45.30
52 WEEK LOW
16.24
MARKET CAP
5.55B
P/E (TTM)
-21.1563
1D
5D
1M
3M
1Y
5Y
1D
Legend Biotech (LEGN) Reports LB2501 Progress, Is The Stock Still Cheap?
Simply Wall St · 1d ago
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
The Motley Fool · 1d ago
Analysts’ Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)
TipRanks · 2d ago
Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of Directors
NASDAQ · 4d ago
CALIDI BIOTHERAPEUTICS APPOINTS FORMER GENENTECH/ROCHE AND CELGENE EXECUTIVE CORSEE SANDERS, PH.D., TO BOARD OF DIRECTORS
Reuters · 5d ago
Why Legend Biotech (LEGN) Is Down 17.3% After $226 Million Follow-On Offering Post LB2501 Data - And What's Next
Simply Wall St · 6d ago
Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion
TipRanks · 6d ago
Legend Biotech prices 7,700,000 ADS follow-on offering at $29.35 each
PUBT · 6d ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.